IRLAB Therapeutics (IRLAB) Q3 2024 earnings summary

Executive summary

• Portfolio includes five first-in-class drug candidates targeting all stages of Parkinson's and related neurological disorders.

• Advanced clinical progress for mesdopetam (preparing for Phase III), pirepemat (Phase IIb completed enrollment), and IRL757 (Phase I ongoing), strengthening position in Parkinson's disease treatments.

• New patents granted for mesdopetam (Europe) and pirepemat (US), extending exclusivity into the 2040s.

• Strategic collaborations and full external funding for IRL757 clinical development, including MSRD/Otsuka partnership.

• Meta-analysis presented at MDS Congress shows mesdopetam's clinically significant anti-dyskinetic effect without impaired motor function.

Financial highlights

• Cash and cash equivalents at Sep 30, 2024: SEK 90.4 million, with SEK 34 million as prepayment for costs covered by partners.

• Net sales for Jan–Sep 2024: SEK 51.8 million, mainly from research collaborations.

• Operating loss for Jan–Sep 2024: SEK -72.1 million, improved from SEK -145.1 million year-over-year.

• Earnings per share: SEK -1.5 (vs. -2.75 in 2023).

• USD 2.5 million milestone payment to be reported in Q4 2024.

Outlook and guidance

• Mesdopetam Phase III program initiation planned; regulatory and market positioning activities ongoing in US and Europe.

• Pirepemat Phase IIb top-line data expected end of Q1 2025.

• IRL757 Phase I studies ongoing, with proof-of-concept study initiation planned and full external funding.

• IRL942 and IRL1117 projected to be Phase I ready in 2025.

• Active pursuit of partnerships, licensing, or capital market transactions to secure future financing.